✦ LIBER ✦

Long-term survivors in metastatic non-small-cell lung cancer: An eastern cooperative oncology group study

Book ID: 123428318
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 179 KB
Volume: 3
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(87)80507-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy of metastatic non-small cel

Chemotherapy of metastatic non-small cell lung cancer (NSCLC): The eastern cooperative oncology group experience

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 178 KB

An Overview of Eastern Cooperative Oncol

An Overview of Eastern Cooperative Oncology Group Stage III Non-Small Cell Lung Cancer Studies

✍ David S. Ettinger 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Phase II trial of acivicin versus etopos

Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer: An Eastern Cooperative Oncology Group study

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Long-term survivors in stage IV non-smal

Long-term survivors in stage IV non-small cell lung cancer

✍ Okamoto, Tatsuro; Maruyama, Riichiroh; Shoji, Fumihiro; Asoh, Hiroshi; Ikeda, Ji 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Long-term survival and toxicity in small

Long-term survival and toxicity in small cell lung cancer: Southwest oncology group study

✍ Robert B. Livingston; Ronald L. Stephens; John D. Bonnet; Petre N. Grozea; Danie 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 327 KB

Phase II study of N-methylformamide, spi

Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): An Eastern cooperative oncology group study

✍ Ettinger, David S. ;Finkelstein, Dianne M. ;Donehower, Ross C. ;Chang, Alex Y. C 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 407 KB

One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with s